Kane Biotech (KNE) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was $8,499, a sharp decline from $1,282,698 in Q3 2024 due to terminated animal health and US distribution agreements.

• Net loss narrowed to $607,345 in Q3 2025 from $678,636 in Q3 2024, despite lower revenue.

• Cash position at September 30, 2025 was $939,062.

• Strategic focus is on advancing wound care in the US through clinical studies, conference presentations, and rebuilding the distributor network.

Financial highlights

• Gross profit turned negative at $(5,128) in Q3 2025, compared to a positive $558,754 in Q3 2024.

• Operating expenses decreased to $538,306 from $1,170,064 year-over-year, mainly due to staff and compensation reductions.

Outlook and guidance

• Ongoing US case series for revyve wound care gel exceeded enrollment targets, with plans to expand the patient database.

• Continued presentations at major wound care conferences and further clinical data releases planned for 2025 and 2026.

• FDA 510(k) clearance submission completed for revyve Antimicrobial Wound Cleanser.